ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN"

Transcription

1 D International Symposium: Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop Fundación Ramón Areces

2 GENERAL INFORMATION DATES OCTOBER 18th 20th VENUE University of Navarra. Pamplona, Spain Modern art museum designed by Rafael Moneo in the University of Navarra main campus (inaugurated in Feb 2015) ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN SYMPOSIUM COORDINATORS Dr. Ignacio Melero Centro de Investigación Médica Aplicada. Clínica Universidad de Navarra. Pamplona Dr. Juan José Lasarte Centro de Investigación Médica Aplicada. Pamplona REGISTRATIONS (FREE OF CHARGE):

3 PROGRAM 18 th October Opening Chair: Jesús San Miguel and Juan José Lasarte Ronald Levy Targeting the Tumor and Targeting the Host. Stanford University Medical Center, Stanford, United States Drew Pardoll Protumorogenic immunity: the dark side of the immune system. Johns Hopkins Medical Institutions, Baltimore, United States BREAK Chair: Ignacio Gil Bazo and Ignacio Melero Jim Allison Immune Checkpoint Blockade in Cancer Therapy: New Insights and Opportunities. MD Anderson Cancer center. Houston. United States Antoni Ribas Melanoma response and resistance to PD 1 blockade UCLA Medical Center. Los Angeles, California, United States 19 th October Chair: Juan José Lasarte George Coukos Understanding tumor microenvironment to optimize immunotherapy. Lessons from ovarian cancer University of Laussane Medical center, Switzerland Ignacio Melero CD137 and friends in immunotherapy combinations. Centro para la Investigación Médica Aplicada Clínica Universidad de Navarra, Pamplona, Spain Sergio Quezada Immune Regulation at the Tumour Site. UCL Cancer Institute, London, United Kingdom Questions BREAK

4 Chair: José Luis Pérez Gracia Suzanne Topalian PD 1 pathway blockade: a common denominator treatment approach mediates a personalized response. Johns Hopkins Medical Institutions, Baltimore, United States Mario Sznol Immune Therapy of Advanced Melanoma based on Immune Checkpoint Inhibitors. School of medicine of Yale. New Haven. United States Pam Sharma Immunotherapy frontiers against prostate and bladder cancer. MD Anderson Cancer Center. Houston. United States Questions LUNCH Chair: Pedro Berraondo Tim Chan Cancer genomes and immunotherapy efficacy. Memorial Sloan Kettering Cancer Center, New York city, United States Sandra Demaria Mechanisms of synergy of radiotherapy with antibodies targeting negative immune regulators in the tumor microenvironment. New York University School of Medicine. New York city, United States Janice Taube Tumor markers of response and resistance to PD 1/PD L1 checkpoint blockade. Johns Hopkins Hospital. Baltimore. United States Questions 20 th October Chair: Ignacio Melero Cornelis Melief Therapeutic cancer vaccines and their application in combination treatment of cancer Leiden University Medical Centre. ISA Pharmaceuticals. Leiden, The Netherlands Caroline Robert Melanoma management : New Treatments and new Toxicities Institute Gustave Roussy, Villejuif, France John Haanen Checkpoint inhibitors: who should we treat? The Netherlands Cancer Research Institute. Amsterdam, The Netherlands Questions BREAK

5 Chair: Pablo Sarobe Francisco Sánchez Madrid Leukocyte activation receptor CD69 and ligands: Immunoregulatory role in inflammatory processes. Hospital de la Princesa. Madrid, Spain Juan José Lasarte FOXP3 as a target for Immunotherapy. Centro para la Investigación Médica Aplicada. Pamplona, Spain María Luisa Toribio Therapeutic antibody targeting of human T cell acute lymphoblastic leukemia initiang cells. Centro de Biología Molecular Severo Ochoa. Madrid, Spain Mario Colombo Multiple layers of immunoregulation: the myeloid connection. Instituto Nazionale Tumori Experimental Oncology. Milan, Italy Questions LUNCH Chair: Mario Colombo Rienk Offringa "A rational approach towards implementation of immunotherapy for pancreatic ductal adenocarcinoma. German Cancer Research Center, Heidelberg, Germany Christian Ottensmaier Genomic assessment of tumour immune profiles in head and neck cancer. University of Southampton School of Medicine, Southampton, United Kingdom Questions BREAK Chair: Rienk Offringa Paolo Ascierto Combining checkpoint inhibition maximizing the body s immune response to cancers. Fondazione Pascale Istituto Nazionale Tumori di Napoli, Italy Martin Glennie Designing immunostimulatory anti TNFR mab to promote anti cancer immunity. University of Southampton School of Medicine, Southampton, United Kingdom Questions Closing remarks

6 Additional sponsors: ASTRA ZENECA BRISTOL MYERS SQUIBBS MSD ROCHE With the collaboration: CIMA CUN EUFP7 IACT GETICA GEIT REINCA IdiSNA

PROGRAMMA SCIENTIFICO

PROGRAMMA SCIENTIFICO PROGRAMMA SCIENTIFICO MELANOMA BRIDGE 2012, DECEMBER 2 ND -4 TH 2012 Presidents: Paolo A. Ascierto, Francesco M. Marincola and Nicola Mozzillo Scientific Board Paolo A. Ascierto Gennaro Ciliberto Bernard

More information

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio

10 th EADO Congress Vilnius, 7-10 May 2014. Ipilimumab update. Michele Maio 10 th EADO Congress Vilnius, 7-10 May 2014 Ipilimumab update Michele Maio Medical Oncology and Immunotherapy, Department of Oncology University Hospital of Siena, Istituto Toscano Tumori SIENA, ITALY Evolving

More information

Promises and challenges of developing new drugs in oncology

Promises and challenges of developing new drugs in oncology 3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San

More information

Promises and challenges of developing new drugs in oncology

Promises and challenges of developing new drugs in oncology 3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San

More information

Patronage requested A. ANICHINI (MILAN) M.P. COLOMBO (MILAN) V. BRONTE (VERONA) M. DEL VECCHIO (MILAN) M. DI NICOLA (MILAN) M.

Patronage requested A. ANICHINI (MILAN) M.P. COLOMBO (MILAN) V. BRONTE (VERONA) M. DEL VECCHIO (MILAN) M. DI NICOLA (MILAN) M. Patronage requested Faculty A. ANICHINI (MILAN) M.P. COLOMBO (MILAN) V. BRONTE (VERONA) M. DEL VECCHIO (MILAN) M. DI NICOLA (MILAN) M. FIGINI (MILAN) J. GALON (PARIS) G. KROEMER (PARIS) M. MAIO (SIENA)

More information

Scientific Programme

Scientific Programme Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico

More information

CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010

CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010 CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010 Organisers S. Gail Eckhardt, University of Colorado Denver, Aurora, USA Roy S. Herbst, The University of Texas MD Anderson

More information

13 May 14 May. SESSION 2.- Advances in hearing loss research II Chair: Andrew Forge

13 May 14 May. SESSION 2.- Advances in hearing loss research II Chair: Andrew Forge 13 May 14 May 15:00-17:00 Registration 15:45-16:00 Welcome on behalf of the organizers José María Millán. Unit of Genetics La Fé Hospital. CIBERER. Valencia. Spain. 16:00-16:30 Francesc Palau. CIBERER

More information

NAPLES - DECEMBER 5-6, 2011 Hotel San Francesco al Monte

NAPLES - DECEMBER 5-6, 2011 Hotel San Francesco al Monte Melanoma Research: A Bridge from Naples to the World th th NAPLES - DECEMBER 5-6, 2011 Hotel San Francesco al Monte Corso Vittorio Emanuele, 328 www.bridgenaples.com (SOCIETY FOR IMMUNOTHERAPY OF CANCER

More information

Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)

Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO) Under the Auspices of Organized by 10th International Symposium Advanced Ovarian Cancer: Optimal Therapy. Update Valencia, Spain, 6th March 2015 Directors Andrés Poveda Fundación Instituto Valenciano de

More information

WORKSHOPS CURRE T TRE DS I BIOMEDICI E

WORKSHOPS CURRE T TRE DS I BIOMEDICI E WORKSHOPS CURRE T TRE DS I BIOMEDICI E 2013 SEDE A TO IO MACHADO BAEZA, SPAI MEMBRA E TRAFFIC AT THE SY APSE. THE CELL BIOLOGY OF SY APTIC PLASTICITY Baeza, Spain 7 th -9 th October 2013 Organized by:

More information

WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region

WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region WORKSHOP IN LUNG CANCER CLINICAL RESEARCH Improving opportunities in the LATAM region April 2016 27-30 Santiago - Chile Hotel Diego de Almagro San Pío X 2530, Providencia, Santiago. INFORMATION www.lungcancerworkshop.cl

More information

Wednesday, February 24 th, 2016

Wednesday, February 24 th, 2016 List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University

More information

Wednesday, February 24 th, 2016

Wednesday, February 24 th, 2016 List of Faculty: Nadeem R. Abu-Rustum, Memorial Sloan Kettering Cancer Center. New York, USA Giovanni Aletti, Istituto Europeo di Oncologia. Milan, Italy Natalia Carballo, David Cibula, General University

More information

Curriculum Vitae of Luca Gianni

Curriculum Vitae of Luca Gianni Education: 1976: State University of Milan, Milan, Italy: Medical Doctor with honors 1981: State University of Milan, Milan, Italy: Board- Certified in Internal Medicine Brief Chronology of Activities

More information

Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom

Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom Scientific Committee Hilary Calvert UCL Cancer Institute, London, United Kingdom Luca Gianni Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy Ana Maria Gonzalez-Angulo M.D. Anderson Cancer

More information

Targeted Therapy What the Surgeon Needs to Know

Targeted Therapy What the Surgeon Needs to Know Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures

More information

Future Oncology: Technology, Products, Market and Service Opportunities

Future Oncology: Technology, Products, Market and Service Opportunities Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter

More information

Immune Therapy for Pancreatic Cancer

Immune Therapy for Pancreatic Cancer Immune Therapy for Pancreatic Cancer December 16, 2014 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll Only:

More information

Immunotherapy Concept Turned Reality

Immunotherapy Concept Turned Reality Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a

More information

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking

This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking Q1/2016 This presentation may contain forward-looking statements, which reflect Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties

More information

HUMAN STEM CELLS DERIVED FROM CORD BLOOD REDUCES THE SIZE OF PANCREATIC TUMOR IN SCID MICE.

HUMAN STEM CELLS DERIVED FROM CORD BLOOD REDUCES THE SIZE OF PANCREATIC TUMOR IN SCID MICE. HUMAN STEM CELLS DERIVED FROM CORD BLOOD REDUCES THE SIZE OF PANCREATIC TUMOR IN SCID MICE. Jay P Sharma***, Saroj K. Basak ++ ***CELPROGEN INC., SAN PEDRO, CA 90731; ++ University of California (UCLA),

More information

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S.

PROSPETTIVE FUTURE NEL TRATTAMENTO. Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. PROSPETTIVE FUTURE NEL TRATTAMENTO MEDICO DEL mrcc Cinzia Ortega Dipartimento di Oncologia Medica Fondazione del Piemonte per l Oncologia I.R.C.C.S. Candiolo Future strategies in mrcc Improve therapeutic

More information

T u m o r D o r m a n c y

T u m o r D o r m a n c y 1 st O N COLille Symposium on T u m o r D o r m a n c y June 26, 2014 Lille, France Invited Speakers Julio Aguirre-Ghiso, Tisch Cancer Institute, New-York, USA Dormancy - Micrometastasis Marieke Essers,

More information

Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy

Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy Predictive Biomarkers for PD1 Pathway Inhibitor Immunotherapy Michael B. Atkins, M.D. Deputy Director Georgetown-Lombardi Comprehensive Cancer Center Michael Atkins, MD Consulting Fees (e.g., advisory

More information

Scientific Programme

Scientific Programme Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo The University of Texas, MD Anderson

More information

Melanoma and Immunotherapy

Melanoma and Immunotherapy Melanoma and Immunotherapy Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA The Transformed Landscape

More information

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma

The Multiple Myeloma Research Foundation Webinar Series Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Improving the Overall Understanding of Immunotherapy in Multiple Myeloma Webinar 3, September 17, 2015 Engineering the Immune System to Recognize Myeloma Cells Speakers Moderator: David Avigan, MD Harvard

More information

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.

More information

Stem cells: the diverging goals of regenerative medicine and oncology ROME JULY 1-2, 2010 CALL FOR ABSTRACTS

Stem cells: the diverging goals of regenerative medicine and oncology ROME JULY 1-2, 2010 CALL FOR ABSTRACTS Preliminary Programme INTERNATIONAL CONFERENCE Promoted by: Consiglio Nazionale delle Ricerche In collaboration with Stem cells: the diverging goals of regenerative medicine and oncology CHAIRMEN: KENNETH

More information

E UROPEAN PERSONAL INFORMATION

E UROPEAN PERSONAL INFORMATION E UROPEAN CURRICULUM VITAE FORMAT PERSONAL INFORMATION Name Work Address ARTURO CHITI Humanitas University, Via A. Manzoni 113, 20089 Rozzano (MI), Italy Nuclear Medicine Department, Humanitas Research

More information

Speakers * * ** * * * * * * * * * * * * * * * * ** * * * * * * * ** * * * * ** * * * * * * ** * * * * * * * *

Speakers * * ** * * * * * * * * * * * * * * * * ** * * * * * * * ** * * * * ** * * * * * * ** * * * * * * * * Quasispecies: past, present and future 30 th anniversary VIII Jornada de Virologia SCB November 17-18, 2008 Institut d Estudis Catalans, Barcelona, Spain Speakers Christof Biebricher Albert Bosch Carlos

More information

ASCO 12. PD-1 Immunotherapy Makes a Splash at ASCO

ASCO 12. PD-1 Immunotherapy Makes a Splash at ASCO PD-1 Immunotherapy Makes a Splash at ASCO By Gregory R. Wolfe, PhD Epigenetic variation and genetic instability in tumor cells yield a variety of tumor antigens that the immune system can recognize to

More information

Immuno-Oncology Therapies to Treat Lung Cancer

Immuno-Oncology Therapies to Treat Lung Cancer Immuno-Oncology Therapies to Treat Lung Cancer What you need to know ONCHQ14NP07519 Introduction: Immuno-oncology represents an innovative approach to cancer research that seeks to harness the body s own

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

Immune Checkpoint Blockade in Acute Myeloid Leukemia. Kinsey McCormick Hematology Fellow s Conference January 10, 2014

Immune Checkpoint Blockade in Acute Myeloid Leukemia. Kinsey McCormick Hematology Fellow s Conference January 10, 2014 Immune Checkpoint Blockade in Acute Myeloid Leukemia Kinsey McCormick Hematology Fellow s Conference January 10, 2014 Overview Overview of immune checkpoints Immune checkpoints as mechanism of immune evasion

More information

A novel molecular mechanism involved in cancer development revealed by targeting MafB to hematopoietic progenitors

A novel molecular mechanism involved in cancer development revealed by targeting MafB to hematopoietic progenitors A novel molecular mechanism involved in cancer development revealed by targeting MafB to hematopoietic progenitors Carolina Vicente Dueñas Instituto de Biología Molecular y Celular del Cáncer (IBMCC) (CSIC-Universidad

More information

Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation

Data from an interim analysis from the pivotal Phase 3 trial of YONDELIS in soft tissue sarcoma, SAR-3007, will be presented in an oral presentation PharmaMar announces new advances in oncology at ASCO 2015 for its compounds YONDELIS and PM1183 in small cell lung cancer, soft tissue sarcoma, and mesothelioma Compelling clinical activity of PM1183 in

More information

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds

NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.

More information

Coordinating Immune Checkpoint Blockade For Cancer Immunotherapy In Combination

Coordinating Immune Checkpoint Blockade For Cancer Immunotherapy In Combination Coordinating Immune Checkpoint Blockade For Cancer Immunotherapy In Combination Jennifer Mataraza, Ph.D. Senior Investigator Immune Oncology, NIBR March 25, 2015 (Image: Steve Gshmeisserner/Science Photo

More information

ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10

ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10 ESO INSIDE TRACK CONFERENCE MADRID 07/06/10 4 th FAMILIAL CANCER CONFERENCE 7-8 June 2010 Madrid, Spain Chair: J. Benítez, ES - H. Vasen, NL APPLICATION AND ABSTRACT SUBMISSION Poster abstract deadline

More information

PRELIMINARY PROGRAM. MELANOMA BRIDGE 2015 Hotel Excelsior, Naples, Italy Sala Partenope December 1-4, 2015

PRELIMINARY PROGRAM. MELANOMA BRIDGE 2015 Hotel Excelsior, Naples, Italy Sala Partenope December 1-4, 2015 PRELIMINARY PROGRAM MELANOMA BRIDGE 2015 Hotel Excelsior, Naples, Italy Sala Partenope December 1-4, 2015 December 1 st Opening Ceremony 5:00 PM Opening Ceremony with "patients meet the experts" Session

More information

Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview

Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Brochure More information from http://www.researchandmarkets.com/reports/3066973/ Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Description:

More information

Resolving Cancer Heterogeneity:

Resolving Cancer Heterogeneity: INTERNATIONAL SYMPOSIUM ON: Resolving Cancer Heterogeneity: The way to personalised medicine Palazzo della Gran Guardia Verona (Italy), June 30 th July 2 nd, 2016 PROGRAM Organized by: ARC-Net Centre for

More information

High Risk and Prevention

High Risk and Prevention Wednesday, April 28, 2010 Time Topic Presenter Aims 09:00-09:15 Welcome Dr. J.C. Acevedo & Kent C. Osborne, MD To give the welcome and explain some particularities of the actual meeting. High Risk and

More information

2011 IRCC International Conference Molecular Clinical Oncology May 26th-28th, 2011, Torino Italy

2011 IRCC International Conference Molecular Clinical Oncology May 26th-28th, 2011, Torino Italy Updated May 23rd, 2011 2011 IRCC International Conference Molecular Clinical Oncology May 26th-28th, 2011, Torino Italy Thursday May 26 th, 2011 (afternoon) Venue: Aula Magna Rettorato 14.00 16.00 Registration

More information

Cambia l algoritmo terapeutico

Cambia l algoritmo terapeutico X Seminario I.T.M.O. Neoplasie a bassa incidenza Istituto di Oncologia Policlinico di Monza Monza 07 Maggio2012? Cambia l algoritmo terapeutico Michele Maio Medical Oncology and Immunotherapy, Department

More information

International Symposium on Malignant Mesothelioma 2011 -- curemeso.org

International Symposium on Malignant Mesothelioma 2011 -- curemeso.org Measles virotherapy for malignant mesothelioma Manish R. Patel, D.O. Assistant Professor of Medicine University of Minnesota June 25, 2011 Medical Treatment of Mesothelioma Majority of patients are not

More information

Enhancing Anti-Tumor Activity of Checkpoint Inhibition

Enhancing Anti-Tumor Activity of Checkpoint Inhibition Enhancing Anti-Tumor Activity of Checkpoint Inhibition Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Laboratory of Tumor

More information

Midwinter Conference 2015 January 17-22 Seefeld, Tyrol CONFERENCE PROGRAM. midwinter2015.org. Sponsored by

Midwinter Conference 2015 January 17-22 Seefeld, Tyrol CONFERENCE PROGRAM. midwinter2015.org. Sponsored by Midwinter Conference 2015 January 17-22 Seefeld, Tyrol CONFERENCE PROGRAM Sponsored by SATURDAY, 17 January 18.00-19.00 Keynote lecture Richard Flavell Sponsored by 19.00 Welcome Reception Hosted by SUNDAY,

More information

High Risk and Prevention

High Risk and Prevention Wednesday, April 28, 2010 Time Topic Presenter Aims 09:00-09:15 Welcome J.C. Acevedo & Kent C. Osborne, MD High Risk and Prevention To give the welcome and explain some particularities of the actual meeting

More information

Attached from the following page is the press release made by BMS for your information.

Attached from the following page is the press release made by BMS for your information. November 19, 2014 Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naïve Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase

More information

II ANNUAL IMMUNOONCOLOGY CONGRESS CIUDAD OBREGON, SONORA, MEXICO. Preliminary program

II ANNUAL IMMUNOONCOLOGY CONGRESS CIUDAD OBREGON, SONORA, MEXICO. Preliminary program 1 II ANNUAL IMMUNOONCOLOGY CONGRESS CIUDAD OBREGON, SONORA, MEXICO Preliminary program Workshops: Thursday December 1 st Congress: Friday December 2 nd and Saturday December 3rd nd. Thursday, December

More information

isbtc/sitc Exceptional Service Award Recipients

isbtc/sitc Exceptional Service Award Recipients isbtc/sitc Exceptional Service Award Recipients Awarded October 3, 2010 for distinguished leadership, continued contribution, and consummate dedication which fostered the growth and success of isbtc. Michael

More information

California s Cancer Clinical Trial Law: What It Means for Physicians

California s Cancer Clinical Trial Law: What It Means for Physicians California s Cancer Clinical Trial Law: What It Means for Physicians The law offers patients a measure of financial security, because it gives them the freedom to enroll in selected clinical trials, with

More information

Latest advances in the treatment of mesothelioma

Latest advances in the treatment of mesothelioma Latest advances in the treatment of mesothelioma Assoc Prof Thomas John Medical Oncologist, NHMRC Fellow Olivia Newton-John Cancer Research Institute 28 th March 2015 Disclosures Nil relevant Honoraria:

More information

Personalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease

Personalized, Targeted Treatment Options Offer Hope of Multiple Myeloma as a Chronic Disease /publications/targeted-therapy-news/2012/november-2012/personalized-targeted-treatment-options- Offer-Hope-of-Multiple-Myeloma-as-a-Chronic-Disease Personalized, Targeted Treatment Options Offer Hope of

More information

Cancer Vaccine Development for Hepatocellular Carcinoma

Cancer Vaccine Development for Hepatocellular Carcinoma Cancer Vaccine Development for Hepatocellular Carcinoma HEPAVAC aims to develop a highly innovative cancer vaccine approach for hepatocellular carcinoma (HCC). HCC is the third and fifth leading cause

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

David Feltl, M.D., Ph.D., MBA. Structure and organization of cancer care in the Czech Republic. Assessment of outputs and outcomes.

David Feltl, M.D., Ph.D., MBA. Structure and organization of cancer care in the Czech Republic. Assessment of outputs and outcomes. David Feltl, M.D., Ph.D., MBA Structure and organization of cancer care in the Czech Republic. Assessment of outputs and outcomes. Contents Cancer epidemiology in the Czech Republic National oncology program

More information

I Advanced Course Clinical and Molecular Virology

I Advanced Course Clinical and Molecular Virology 2 nd announcement I Advanced Course Clinical and Molecular Virology 9-20 May 2016 Porto, Portugal Scientific/Organizing Commitee Hugo Sousa (Virology Service, IPO Porto, Porto PT) Rui Medeiros (Virology

More information

Foundational Issues Related to Immunotherapy and Melanoma

Foundational Issues Related to Immunotherapy and Melanoma Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including

More information

TEACH Summer School Cascais, Portugal 3-7 July, 2016. Training and Education for Advanced Clinicians and HCPs in Personalised Medicine

TEACH Summer School Cascais, Portugal 3-7 July, 2016. Training and Education for Advanced Clinicians and HCPs in Personalised Medicine TEACH Summer School Cascais, Portugal 3-7 July, 2016 Training and Education for Advanced Clinicians and HCPs in Personalised Medicine TEACH Summer School Cascais, Portugal 3-7 July, 2016 Objectives There

More information

ESSO Course on Peritoneal Surface Malignancy

ESSO Course on Peritoneal Surface Malignancy ESSO Course on Peritoneal Surface Malignancy In partnership with The Christie School of Oncology 08-09 October 2015 MANCHESTER (UK) ESSO Course on Peritoneal Surface Malignancy Chair: Sarah O Dwyer, The

More information

Equity markets Major advances in cancer therapeutics 18 August 2015

Equity markets Major advances in cancer therapeutics 18 August 2015 Major advances in cancer therapeutics 18 August 2015 CIO WM Research Jerome Brimeyer, Equity Sector Strategist, jerome.brimeyer@ubs.com Our cancer therapeutics investment theme recommends companies that

More information

ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10

ESO INSIDE TRACK CONFERENCE. 4 th FAMILIAL CANCER CONFERENCE. 7-8 June 2010 Madrid, Spain. Chair: J. Benítez, ES - H. Vasen, NL MADRID 07/06/10 ESO INSIDE TRACK CONFERENCE MADRID 07/06/10 4 th FAMILIAL CANCER CONFERENCE 7-8 June 2010 Madrid, Spain Chair: J. Benítez, ES - H. Vasen, NL APPLICATION AND ABSTRACT SUBMISSION Poster abstract deadline

More information

CURRENT AND FUTURE CHALLENGES OF INNOVATIVE ONCOLOGY DRUG DEVELOPMENT

CURRENT AND FUTURE CHALLENGES OF INNOVATIVE ONCOLOGY DRUG DEVELOPMENT CDDF Cancer Drug Development Forum CDDF 8 TH ALPINE CONFERENCE CURRENT AND FUTURE CHALLENGES OF INNOVATIVE ONCOLOGY DRUG DEVELOPMENT INNSBRUCK, AUSTRIA 2-4 MARCH 2015 Workshop objectives The goal of the

More information

FARMACI PERSONALIZZATI PER

FARMACI PERSONALIZZATI PER ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI FONDAZIONE G. Pascale NAPOLI SC Biologia Cellulare e Bioterapie CENTRO RICERCHE ONCOLOGICHE MERCOGLIANO (AV) Laboratorio di Farmacogenomica FARMACI

More information

EACR AACR SIC. from Cancer Biology to the Clinic. Advance Programme & Call for Abstracts ITALY 20-23 JUNE. Anticancer Drug Action and Drug Resistance:

EACR AACR SIC. from Cancer Biology to the Clinic. Advance Programme & Call for Abstracts ITALY 20-23 JUNE. Anticancer Drug Action and Drug Resistance: Anticancer Drug Action and Drug Resistance: from Cancer Biology to the Clinic Organised by: Advance Programme & Call for Abstracts -- ORGANIZING COMMITTEE n Richard Marais (UK) - Conference Co-Chair n

More information

Advances in Biology and Treatment of Malignant Brain Gliomas

Advances in Biology and Treatment of Malignant Brain Gliomas Advances in Biology and Treatment of Malignant Brain Gliomas International Congress 2 nd Edition Rome, June 12-13, 2014 President Giulio Maira Vice Presidents Ruggero De Maria, Antonio Iavarone, Angelo

More information

California s Cancer Clinical Trial Law:

California s Cancer Clinical Trial Law: California s Cancer Clinical Trial Law: A clinical trial is a study of a treatment or treatments to find out how well they work in certain patients. Introduction If you are a cancer patient, you and your

More information

MADRID 11/06/09 EPIGENETICS AND NEW THERAPIES IN CANCER. 11-12 June 2009 Madrid, Spain ESO INSIDE TRACK CONFERENCE

MADRID 11/06/09 EPIGENETICS AND NEW THERAPIES IN CANCER. 11-12 June 2009 Madrid, Spain ESO INSIDE TRACK CONFERENCE ESO INSIDE TRACK CONFERENCE MADRID 11/06/09 EPIGENETICS AND NEW THERAPIES IN CANCER 11-12 June 2009 Madrid, Spain Chair: M. Esteller, ES Coordinators: S. Marsoni, IT - M.A. Piris, ES APPLICATION AND ABSTRACT

More information

The Past, Present & Future of Cancer Immunotherapy:

The Past, Present & Future of Cancer Immunotherapy: Article The Past, Present & Future of Cancer Immunotherapy: An Overview Recently BioWorld called cancer immunotherapy white hot based on unprecedented investments in private companies, partnerships between

More information

Your Immune System & Cancer Treatment

Your Immune System & Cancer Treatment Your Immune System & Cancer Treatment Immunotherapy Today, immunotherapy is one of the most exciting areas of new discoveries and treatments for many different kinds of cancer. Researchers now know that

More information

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05 Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel #38 2014-05 Therapeutic Area:

More information

2.1.1. - MEDICINE BACHELOR School of Medicine. Universidad de Concepción Chile. 01.24,1973

2.1.1. - MEDICINE BACHELOR School of Medicine. Universidad de Concepción Chile. 01.24,1973 C U R R I C U L U M V I T A E 1. - PERSONAL RECORDS Family name : Casanova First names : Egon Reginaldo Date of birth : September 12, 1944 Nationality : Chilean Mail : email; ecasanov@udec.cl Web page

More information

Trials in Elderly Melanoma Patients (with a focus on immunotherapy)

Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP

More information

Programme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy

Programme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy Programme Invited Speakers: Reuven Agami (The Netherlands), Manuela Baccarini (Austria), Allan Balmain (USA), Daniel Birnbaum (France), Anne-Lise Børresen-Dale (Norway), Carlos Caldas (UK), Silvana Canevari

More information

Biomedicine The background. The main interest. The tools

Biomedicine The background. The main interest. The tools 1 Biomedicine The background The main interest? Bioinformatics Clinical informatics The tools 2 Outline 3 Outline 4 Working on Network Data Analysis HH RR Infrastructure Training BIOCOMPUTATION & STRUCTURAL

More information

Curriculum Vitae. Education. Brief Chronology of Employment. Academic Positions held. Pier Paolo Di Fiore M.D. Ph.D.

Curriculum Vitae. Education. Brief Chronology of Employment. Academic Positions held. Pier Paolo Di Fiore M.D. Ph.D. Pier Paolo Di Fiore M.D. Ph.D. Curriculum Vitae Education 1981 - M.D., summa cum laude, University of Naples, 2nd Medical School, Naples, Italy 1984 - Board in Oncology, summa cum laude, University of

More information

Ph.D. in Molecular Medicine

Ph.D. in Molecular Medicine Ph.D. in Molecular Medicine and Translational Research College of Medicine 1. Introduction: The College of Medicine, while consolidating on its undergraduate innovative educational programs, decided to

More information

Pablo Ruiz Verdú. Universidad Carlos III de Madrid Tel.: +34-91 624 5801 Department of Business Administration Fax: +34-91 624 9607

Pablo Ruiz Verdú. Universidad Carlos III de Madrid Tel.: +34-91 624 5801 Department of Business Administration Fax: +34-91 624 9607 Pablo Ruiz Verdú Universidad Carlos III de Madrid Tel.: +34-91 624 5801 Department of Business Administration Fax: +34-91 624 9607 Calle Madrid, 126. 28903-Getafe E-mail: pablo.ruiz@uc3m.es Madrid, Spain

More information

Departments of Nuclear Medicine, Surgery, and Endocrinology University of Ulm

Departments of Nuclear Medicine, Surgery, and Endocrinology University of Ulm 4 th Würzburg Summer School of Thyroid Cancer Management A training course on basics, diagnosis and therapy of differentiated thyroid tumours under the auspices of the European Association of Nuclear Medicine

More information

Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France 11-14 September 2008

Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France 11-14 September 2008 33 rd European Symposium on Hormones and Cell Regulation Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers Mont Ste. Odile, Alsace, France 11-14 September 2008 Invited Speakers:

More information

PROGRAM FOR THE CONFERENCE. Frontiers in Cancer Research and Therapy. Karolinska Institutet, Nobel Forum, March 5-6, 2015

PROGRAM FOR THE CONFERENCE. Frontiers in Cancer Research and Therapy. Karolinska Institutet, Nobel Forum, March 5-6, 2015 Photo: Science Photo Library PROGRAM FOR THE CONFERENCE F 2015 Frontiers in Cancer Research and Therapy Karolinska Institutet, Nobel Forum, March 5-6, 2015 5 MARCH 2015, THURSDAY, NOBEL FORUM KAROLINSKA

More information

FDA grants Roche s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer

FDA grants Roche s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer Media Release Basel, 19 May 2016 FDA grants Roche s cancer immunotherapy Tecentriq (atezolizumab) accelerated approval for people with a specific type of advanced bladder cancer First and only anti-pd-l1

More information

16 TH -17 TH INNOVATIONS IN ONCOLOGY NOVEMBER HEIDELBERG

16 TH -17 TH INNOVATIONS IN ONCOLOGY NOVEMBER HEIDELBERG 16 TH -17 TH 2015 NOVEMBER INNOVATIONS IN ONCOLOGY HEIDELBERG INNOVATIONS IN ONCOLOGY HEIDELBERG, NOVEMBER 16 TH - 17 TH 2015 German Cancer Research Center (DKFZ) Heidelberg - Germany Hosted by the National

More information

eso InSIDe TrACK COnferenCe CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl

eso InSIDe TrACK COnferenCe CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl eso InSIDe TrACK COnferenCe 6 TH familial CAnCer COnferenCe 5-6 June 2014 Madrid, Spain Chairs: j. Benítez, es R. eeles, uk H. Vasen, nl Dear Colleagues, The 6th Familial Cancer Conference hosted once

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

Building A Focused Oncology Business

Building A Focused Oncology Business Building A Focused Oncology Business David Meek President, Oncology Our Strategic Priority: To be at the forefront of patient-centric innovation, bringing life-changing cancer therapies to patients with

More information

2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma

2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma 2 nd ESSO Advanced Course on the Surgical and Medical Management of Melanoma Focus on stage III and IV melanoma In partnership with the Society of Surgical Oncology (SSO) 12-14 November 2015 ATHENS (GR)

More information

Education Session 1. Education Session 2. Inaugural Session

Education Session 1. Education Session 2. Inaugural Session WEDNESDAY 4 NOVEMBER 2015 Education Session 1 09:30-10:30 S1a: Cell and viral vector manufacturing and distribution under GMP Chair: Ana Sanchez S1b: Systems biology: computational methods applied to advanced

More information

Curriculum Vitae - Sara Gandini

Curriculum Vitae - Sara Gandini Curriculum Vitae - Sara Gandini Academic information 2004 PHD IN CANCER STUDIES at the University of Birmingham (Public Health), UK. Thesis: Meta-Analysis in Cancer Epidemiology. 1995 MASTER OF SCIENCE

More information

GUSTAVE ROUSSY AT ASCO

GUSTAVE ROUSSY AT ASCO GUSTAVE ROUSSY AT ASCO PRESS RELEASE 30 MAY 03 JUNE MELANOMA www.gustaveroussy.fr/asco 30 MAY 03 JUNE 14 GUSTAVE ROUSSY AT ASCO PRESS RELEASE ASCO MAY 30 th - JUNE 3 rd 50 th congress American Society

More information

Innovation and Teaching Technologies

Innovation and Teaching Technologies Innovation and Teaching Technologies Marta Peris-Ortiz Fernando J. Garrigós-Simón Ignacio Gil Pechuán Editors Innovation and Teaching Technologies New Directions in Research, Practice and Policy Editors

More information

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development

Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from

More information

Oncologist-to-Oncologist: How to Treat Your Patients with Immunotherapy

Oncologist-to-Oncologist: How to Treat Your Patients with Immunotherapy Oncologist-to-Oncologist: How to Treat Your Patients with Immunotherapy Michael A. Postow, M.D. Memorial Sloan Kettering Cancer Center Wednesday, June 10, 2015 11:00 a.m. EDT Brought to you by the Cancer

More information

Anticancer Immunotherapy A New Weapon Against Cancer JON STEPHENS, MPHIL SENIOR ANALYST, ONCOLOGY

Anticancer Immunotherapy A New Weapon Against Cancer JON STEPHENS, MPHIL SENIOR ANALYST, ONCOLOGY Anticancer Immunotherapy A New Weapon Against Cancer JON STEPHENS, MPHIL SENIOR ANALYST, ONCOLOGY A robust new approach Since its inception in the mid-0th century, chemotherapy has been the mainstay of

More information

9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium

9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium 9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) Szeged,

More information